Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda Licenses Amylin Obesity Drugs

by Lisa M. Jarvis
November 9, 2009 | A version of this story appeared in Volume 87, Issue 45

Takeda Pharmaceutical is licensing two obesity drugs in development at Amylin Pharmaceuticals. For a $75 million up-front payment and more than $1 billion in potential milestone payments, the Japanese firm gains access to pramlintide/metreleptin and davalintide, peptides in Phase II clinical trials as obesity treatments. Already approved to control glucose levels, pramlin­tide caused diabetics to lose 6 lb on average in a clinical trial. Researchers have struggled to find a safe and effective weight-loss pill. Last year, Merck & Co., Pfizer, Solvay, and Sanofi-Aventis all pulled obesity drugs from late-stage clinical studies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.